Exhibit 99.1

NPS Pharmaceuticals Reports Financial Results for 2010 and Guidance for 2011

-- Positive GATTEX® Phase 3 STEPS study announced in January; U.S. marketing submission expected in second half 2011 --

-- Patient randomization in NPSP558 Phase 3 REPLACE study to conclude ahead of prior guidance; top-line results now expected in fourth quarter 2011 --

-- Conference call today at 5:00 PM ET --

BEDMINSTER, N.J.--(BUSINESS WIRE)--February 15, 2011--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported its results for 2010 and provided cash burn guidance for 2011.

NPS reported a net loss of $6.4 million or $0.09 per diluted share for the fourth quarter 2010, compared to a net loss of $2.0 million or $0.04 per diluted share for the fourth quarter 2009. For the full year, the company reported a net loss of $31.4 million or $0.54 per diluted share for 2010, versus $17.9 million or $0.37 per diluted share for 2009. The year-over-year changes in the company’s financial results were principally driven by increased research and development expenses of $2.9 million and $25.5 million for the fourth quarter and full year, respectively, due to the advancement of the company’s two Phase 3 registration programs, GATTEX® (teduglutide) in short bowel syndrome (SBS) and NPSP558 in hypoparathyroidism. Cash and investments totaled $133.8 million at December 31, 2010 versus $74.9 million at December 31, 2009.

“In 2010 we achieved our stated objectives and delivered meaningful results across all aspects of our business,” said Francois Nader, MD, president and chief executive officer of NPS Pharmaceuticals. “We recently reported positive top-line data from our Phase 3 STEPS study of GATTEX in short bowel syndrome and expect to submit our U.S. marketing application later this year. We are also pleased with the progress of our NPSP558 pivotal registration study in hypoparathyroidism. We achieved our randomization target ahead of prior guidance and now expect to report top-line results before the end of this year. And we further enhanced our financial position through successful financing activities and delivering full-year cash burn at the low end of our guidance.”


The following information was filed by Nps Pharmaceuticals Inc (NPSP) on Tuesday, February 15, 2011 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Nps Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Nps Pharmaceuticals Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account